XML 62 R50.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2010
cvr
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Assets:            
Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag       Derivative assets(2)   Derivative assets(2)
Liabilities:            
Number of CVR series | cvr 4          
Transferred over Time | Phase 3 clinical trial            
Liabilities:            
Gross contract asset   $ 10,000   $ 10,000    
Maximum | Transferred over Time | Development, regulatory, & commercial milestones and tiered royalties            
Liabilities:            
Investments   375,000   375,000    
Metabasis            
Liabilities:            
Number of CVRs issued per acquiree share | cvr 4          
Number of CVRs issued from each CVR series | cvr 1          
Frequency of cash payments to CVR holders 6 months          
(Decrease) increase of mark-to-market adjustment of CVR liability   (500) $ (200) 1,400 $ 900  
Recurring            
Assets:            
Derivative asset   9,351   9,351   $ 10,583
Total assets   672,475   672,475   194,441
Liabilities:            
Total liabilities   3,837   3,837   3,681
Recurring | Short-Term Investments            
Assets:            
Investments, fair value   525,146   525,146   183,858
Recurring | Preferred Stock            
Assets:            
Investments, fair value   95,978   95,978   0
Recurring | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   390   390   383
Recurring | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   3,447   3,447   3,298
Recurring | Level 1            
Assets:            
Equity method investment in Pelthos   42,000   42,000   0
Derivative asset   0   0   0
Total assets   307,354   307,354   122,047
Liabilities:            
Total liabilities   0   0   0
Recurring | Level 1 | Short-Term Investments            
Assets:            
Investments, fair value   169,376   169,376   122,047
Recurring | Level 1 | Preferred Stock            
Assets:            
Investments, fair value   95,978   95,978   0
Recurring | Level 1 | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   0   0   0
Recurring | Level 1 | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   0   0   0
Recurring | Level 2            
Assets:            
Equity method investment in Pelthos   0   0   0
Derivative asset   0   0   0
Total assets   355,770   355,770   61,811
Liabilities:            
Total liabilities   3,447   3,447   3,298
Recurring | Level 2 | Short-Term Investments            
Assets:            
Investments, fair value   355,770   355,770   61,811
Recurring | Level 2 | Preferred Stock            
Assets:            
Investments, fair value   0   0   0
Recurring | Level 2 | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   0   0   0
Recurring | Level 2 | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   3,447   3,447   3,298
Recurring | Level 3            
Assets:            
Equity method investment in Pelthos   0   0   0
Derivative asset   9,351   9,351   10,583
Total assets   9,351   9,351   10,583
Liabilities:            
Total liabilities   390   390   383
Recurring | Level 3 | Short-Term Investments            
Assets:            
Investments, fair value   0   0   0
Recurring | Level 3 | Preferred Stock            
Assets:            
Investments, fair value   0   0   0
Recurring | Level 3 | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   390   390   383
Recurring | Level 3 | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   $ 0   $ 0   $ 0